{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T02:28:25Z","timestamp":1788488905086,"version":"build-2803163510"},"reference-count":87,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T00:00:00Z","timestamp":1764115200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003086","name":"Eusko Jaurlaritza","doi-asserted-by":"publisher","award":["IT1551-22"],"award-info":[{"award-number":["IT1551-22"]}],"id":[{"id":"10.13039\/501100003086","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003086","name":"Eusko Jaurlaritza","doi-asserted-by":"publisher","award":["BIO23\/EM\/02"],"award-info":[{"award-number":["BIO23\/EM\/02"]}],"id":[{"id":"10.13039\/501100003086","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100015496","name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red sobre Enfermedades Neurodegenerativas","doi-asserted-by":"publisher","award":["CB06\/05\/00"],"award-info":[{"award-number":["CB06\/05\/00"]}],"id":[{"id":"10.13039\/501100015496","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuropharmacology"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.neuropharm.2025.110783","type":"journal-article","created":{"date-parts":[[2025,11,24]],"date-time":"2025-11-24T16:17:04Z","timestamp":1764001024000},"page":"110783","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Purinergic signaling in Stroke and Multiple Sclerosis: Prospects for therapies"],"prefix":"10.1016","volume":"284","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3654-0159","authenticated-orcid":false,"given":"Abraham","family":"Cisneros-Mejorado","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ant\u00f2nia","family":"Colom-Casasnovas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"P\u00e9rez-Samart\u00edn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8672-711X","authenticated-orcid":false,"given":"Carlos","family":"Matute","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.neuropharm.2025.110783_bib1","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.tins.2008.10.001","article-title":"Purinergic signalling in the nervous system: an overview","volume":"32","author":"Abbracchio","year":"2009","journal-title":"Trends Neurosci."},{"issue":"4","key":"10.1016\/j.neuropharm.2025.110783_bib2","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1158\/0008-5472.CAN-14-1259","article-title":"Accelerated tumor progression in mice lacking the ATP receptor P2X7","volume":"75","author":"Adinolfi","year":"2015","journal-title":"Cancer Res."},{"key":"10.1016\/j.neuropharm.2025.110783_bib3","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.3389\/fimmu.2017.01529","article-title":"Modulation of P2X7 receptor during inflammation in multiple sclerosis","volume":"8","author":"Amadio","year":"2017","journal-title":"Front. Immunol."},{"key":"10.1016\/j.neuropharm.2025.110783_bib4","doi-asserted-by":"crossref","DOI":"10.1038\/cddis.2012.105","article-title":"The P2X7 receptor is a key modulator of aerobic glycolysis","volume":"3","author":"Amoroso","year":"2012","journal-title":"Cell Death Dis."},{"issue":"3","key":"10.1016\/j.neuropharm.2025.110783_bib5","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1016\/j.nbd.2011.12.014","article-title":"P2X7 receptor blockade prevents ATP excitotoxicity in neurons and reduces brain damage after stroke","volume":"45","author":"Arbeloa","year":"2012","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.neuropharm.2025.110783_bib6","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1186\/s12974-017-1034-z","article-title":"Purinergic receptors P2Y12R and P2X7R: potential targets for PET imaging of microglia phenotypes in multiple sclerosis","volume":"14","author":"Beaino","year":"2017","journal-title":"J. Neuroinflammation"},{"issue":"50","key":"10.1016\/j.neuropharm.2025.110783_bib7","doi-asserted-by":"crossref","first-page":"52517","DOI":"10.1074\/jbc.M410223200","article-title":"Subunit-specific coupling between \u03b3-Aminobutyric acid type A and P2X2 receptor channels","volume":"279","author":"Bou\u00e9-Grabot","year":"2004","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.neuropharm.2025.110783_bib8","series-title":"Purinergic Signalling and the Nervous System","author":"Burnstock","year":"2012"},{"issue":"6","key":"10.1016\/j.neuropharm.2025.110783_bib9","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1002\/med.21710","article-title":"The purinergic P2X7 receptor as a potential drug target to combat neuroinflammation in neurodegenerative diseases","volume":"40","author":"Calzaferri","year":"2020","journal-title":"Med. Res. Rev."},{"issue":"21","key":"10.1016\/j.neuropharm.2025.110783_bib10","doi-asserted-by":"crossref","first-page":"4631","DOI":"10.1523\/JNEUROSCI.3073-20.2021","article-title":"Altered heterosynaptic plasticity impairs visual discrimination learning in adenosine A1 receptor knock-out mice","volume":"41","author":"Chasse","year":"2021","journal-title":"J. Neurosci."},{"key":"10.1016\/j.neuropharm.2025.110783_bib11","doi-asserted-by":"crossref","DOI":"10.1007\/978-3-031-55529-9_23","article-title":"Role of microglia in stroke","volume":"37","author":"Cipriani","year":"2024","journal-title":"Adv. Neurobiol."},{"issue":"5","key":"10.1016\/j.neuropharm.2025.110783_bib12","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1038\/jcbfm.2014.262","article-title":"Blockade of P2X7 receptors or pannexin-1 channels similarly attenuates postischemic damage","volume":"35","author":"Cisneros-Mejorado","year":"2015","journal-title":"J. Cerebr. Blood Flow Metabol."},{"issue":"1","key":"10.1016\/j.neuropharm.2025.110783_bib13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s10571-014-0092-3","article-title":"ATP signaling in brain: release, excitotoxicity and potential therapeutic targets","volume":"35","author":"Cisneros-Mejorado","year":"2015","journal-title":"Cell. Mol. Neurobiol."},{"key":"10.1016\/j.neuropharm.2025.110783_bib14","doi-asserted-by":"crossref","first-page":"94","DOI":"10.3389\/fnmol.2020.00092","article-title":"P2X7 receptors as a therapeutic target in cerebrovascular diseases","volume":"13","author":"Cisneros-Mejorado","year":"2020","journal-title":"Front. Mol. Neurosci."},{"issue":"2","key":"10.1016\/j.neuropharm.2025.110783_bib15","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/s11302-005-0649-1","article-title":"Neuroprotection by adenosine in the brain: from A1 receptor activation to A2A receptor blockade","volume":"1","author":"Cunha","year":"2005","journal-title":"Purinergic Signal."},{"issue":"3","key":"10.1016\/j.neuropharm.2025.110783_bib16","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1038\/sj.cdd.4400341","article-title":"Cytolytic P2X purinoceptors","volume":"5","author":"Di Virgilio","year":"1998","journal-title":"Cell Death Differ."},{"issue":"1","key":"10.1016\/j.neuropharm.2025.110783_bib17","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.immuni.2017.06.020","article-title":"The P2X7 receptor in infection and inflammation","volume":"47","author":"Di Virgilio","year":"2017","journal-title":"Immunity"},{"key":"10.1016\/j.neuropharm.2025.110783_bib18","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.coph.2019.03.010","article-title":"Targeting P2X4 and P2X7 receptors in multiple sclerosis","volume":"47","author":"Domercq","year":"2019","journal-title":"Curr. Opin. Pharmacol."},{"issue":"6","key":"10.1016\/j.neuropharm.2025.110783_bib19","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1002\/glia.20958","article-title":"P2X7 receptors mediate ischemic damage to oligodendrocytes","volume":"58","author":"Domercq","year":"2010","journal-title":"Glia"},{"issue":"7","key":"10.1016\/j.neuropharm.2025.110783_bib20","first-page":"49","article-title":"Neurotransmitter signaling in the pathophysiology of microglia","volume":"19","author":"Domercq","year":"2013","journal-title":"Front. Cell. Neurosci."},{"issue":"1","key":"10.1016\/j.neuropharm.2025.110783_bib21","doi-asserted-by":"crossref","DOI":"10.1038\/srep16222","article-title":"Modulation of P2X 4\/P2 X7\/Pannexin-1 sensitivity to extracellular ATP via ivermectin induces a non-apoptotic and inflammatory form of cancer cell death","volume":"5","author":"Draganov","year":"2015","journal-title":"Sci. Rep."},{"issue":"7","key":"10.1016\/j.neuropharm.2025.110783_bib22","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1038\/s41401-023-01061-2","article-title":"Angiogenesis after ischemic stroke","volume":"44","author":"Fang","year":"2023","journal-title":"Acta Pharmacol. Sin."},{"issue":"10","key":"10.1016\/j.neuropharm.2025.110783_bib23","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/S1474-4422(21)00252-0","article-title":"Global, regional, and national burden of stroke and its risk factors, 1990\u20132019: a systematic analysis for the global burden of disease study 2019","volume":"20","author":"Feigin","year":"2021","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.neuropharm.2025.110783_bib24","doi-asserted-by":"crossref","first-page":"399","DOI":"10.3389\/fphar.2018.00399","article-title":"The selective antagonism of adenosine A2B receptors reduces the synaptic failure and neuronal death induced by oxygen and glucose deprivation in rat CA1 hippocampus in vitro","volume":"9","author":"Fusco","year":"2018","journal-title":"Front. Pharmacol."},{"issue":"2","key":"10.1016\/j.neuropharm.2025.110783_bib25","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1007\/s00018-018-2937-2","article-title":"The role of P2Y12 receptor in ischemic stroke of atherosclerotic origin","volume":"76","author":"Gao","year":"2019","journal-title":"Cell. Mol. Life Sci."},{"issue":"2","key":"10.1016\/j.neuropharm.2025.110783_bib26","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.neuron.2015.05.041","article-title":"Novel stroke therapeutics: unraveling stroke pathophysiology and its impact on clinical treatments","volume":"87","author":"George","year":"2015","journal-title":"Neuron"},{"issue":"7","key":"10.1016\/j.neuropharm.2025.110783_bib27","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1111\/ejn.12851","article-title":"Adenosine A2b receptors control A1 receptor\u2010mediated inhibition of synaptic transmission in the mouse hippocampus","volume":"41","author":"Gon\u00e7alves","year":"2015","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.neuropharm.2025.110783_bib29","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/s10787-018-0528-3","article-title":"Early P2X7R-dependent activation of microglia during the asymptomatic phase of autoimmune encephalomyelitis","volume":"27","author":"Grygorowicz","year":"2018","journal-title":"Inflammopharmacol"},{"key":"10.1016\/j.neuropharm.2025.110783_bib30","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.mcn.2016.02.003","article-title":"Early P2X7R-related astrogliosis in autoimmune encephalomyelitis","volume":"74","author":"Grygorowicz","year":"2016","journal-title":"Mol. Cell. Neurosci."},{"key":"10.1016\/j.neuropharm.2025.110783_bib31","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1007\/s11302-018-9620-9","article-title":"Administration of an antagonist of P2X7 receptor to EAE rats prevents a decrease of expression of claudin-5 in cerebral capillaries","volume":"14","author":"Grygorowicz","year":"2018","journal-title":"Purinergic Signal."},{"issue":"21","key":"10.1016\/j.neuropharm.2025.110783_bib32","doi-asserted-by":"crossref","first-page":"4195","DOI":"10.1111\/bph.14470","article-title":"P2X7 as scavenger receptor for innate phagocytosis in the brain","volume":"175","author":"Gu","year":"2018","journal-title":"Br. J. Pharmacol."},{"issue":"20","key":"10.1016\/j.neuropharm.2025.110783_bib33","doi-asserted-by":"crossref","first-page":"5644","DOI":"10.1093\/hmg\/ddv278","article-title":"A rare P2X7 variant Arg307Gln with absent pore formation function protects against neuroinflammation in multiple sclerosis","volume":"24","author":"Gu","year":"2015","journal-title":"Hum. Mol. Genet."},{"issue":"11","key":"10.1016\/j.neuropharm.2025.110783_bib34","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1038\/nrneurol.2013.174","article-title":"Mild acute ischaemic stroke--the case for thrombolytic therapy","volume":"9","author":"Guerrero","year":"2013","journal-title":"Nat. Rev. Neurol."},{"issue":"1","key":"10.1016\/j.neuropharm.2025.110783_bib35","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.neuroscience.2005.04.026","article-title":"Lesional accumulation of P2X(4) receptor(+) macrophages in rat CNS during experimental autoimmune encephalomyelitis","volume":"134","author":"Guo","year":"2005","journal-title":"Neuroscience"},{"issue":"2","key":"10.1016\/j.neuropharm.2025.110783_bib36","doi-asserted-by":"crossref","first-page":"187","DOI":"10.2967\/jnumed.116.185975","article-title":"Validation of MRI determination of the penumbra by PET measurements in ischemic stroke","volume":"58","author":"Heiss","year":"2017","journal-title":"J. Nucl. Med."},{"issue":"1","key":"10.1016\/j.neuropharm.2025.110783_bib37","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1038\/s41392-021-00553-z","article-title":"From purines to purinergic signalling: molecular functions and human diseases","volume":"6","author":"Huang","year":"2021","journal-title":"Signal Transduct. Targeted Ther."},{"issue":"7","key":"10.1016\/j.neuropharm.2025.110783_bib38","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1038\/nm.2399","article-title":"The immunology of stroke: from mechanisms to translation","volume":"17","author":"Iadecola","year":"2011","journal-title":"Nat. Med."},{"issue":"6","key":"10.1016\/j.neuropharm.2025.110783_bib39","doi-asserted-by":"crossref","first-page":"2777","DOI":"10.1172\/JCI135530","article-title":"Immune responses to stroke: mechanisms, modulation, and therapeutic potential","volume":"130","author":"Iadecola","year":"2020","journal-title":"J. Clin. Investig."},{"issue":"17","key":"10.1016\/j.neuropharm.2025.110783_bib40","doi-asserted-by":"crossref","first-page":"5996","DOI":"10.3390\/ijms21175996","article-title":"P2X7 receptors amplify CNS damage in neurodegenerative diseases","volume":"21","author":"Illes","year":"2020","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.neuropharm.2025.110783_bib41","first-page":"2788","article-title":"P2X and P2Y receptor antagonists reduce inflammation in ATP-induced microglia","volume":"21","author":"Imraish","year":"2022","journal-title":"Pharm. Pract."},{"issue":"22","key":"10.1016\/j.neuropharm.2025.110783_bib42","doi-asserted-by":"crossref","first-page":"19993","DOI":"10.1074\/jbc.M111.231324","article-title":"Cross-talk between P2X4 and \u03b3-Aminobutyric acid, type A receptors determines synaptic efficacy at a central synapse","volume":"286","author":"Jo","year":"2011","journal-title":"J. Biol. Chem."},{"issue":"12","key":"10.1016\/j.neuropharm.2025.110783_bib43","doi-asserted-by":"crossref","first-page":"3259","DOI":"10.1111\/j.1460-9568.2006.04861.x","article-title":"Cross\u2010inhibitory interactions between GABAA and P2X channels in myenteric neurons","volume":"23","author":"Karanjia","year":"2006","journal-title":"Eur. J. Neurosci."},{"issue":"1","key":"10.1016\/j.neuropharm.2025.110783_bib44","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms10555","article-title":"Neutrophil P2X7 receptors mediate NLRP3 inflammasome-dependent IL-1\u03b2 secretion in response to ATP","volume":"7","author":"Karmakar","year":"2016","journal-title":"Nat. Commun."},{"key":"10.1016\/j.neuropharm.2025.110783_bib45","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1007\/s12035-014-8879-2","article-title":"A2A adenosine receptor regulates the human blood-brain barrier permeability","volume":"52","author":"Kim","year":"2015","journal-title":"Mol. Neurobiol."},{"issue":"1","key":"10.1016\/j.neuropharm.2025.110783_bib46","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/s41421-025-00797-x","article-title":"Structural insight into the self-activation and G-protein coupling of P2Y2 receptor","volume":"11","author":"Lan","year":"2025","journal-title":"Cell Discov."},{"issue":"8","key":"10.1016\/j.neuropharm.2025.110783_bib47","doi-asserted-by":"crossref","first-page":"2401","DOI":"10.1002\/eji.200939838","article-title":"Oxidized ATP inhibits T-cell-mediated autoimmunity","volume":"40","author":"Lang","year":"2010","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.neuropharm.2025.110783_bib48","doi-asserted-by":"crossref","first-page":"2869","DOI":"10.1111\/ene.15360","article-title":"The contribution of neuropathology to multiple sclerosis research","volume":"29","author":"Lassmann","year":"2022","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.neuropharm.2025.110783_bib49","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1007\/s11239-020-02098-4","article-title":"The role of P2Y12 receptor inhibition in ischemic stroke on microglia, platelets and vascular smooth muscle cells","volume":"50","author":"Li","year":"2020","journal-title":"J. Thromb. Thrombolysis"},{"issue":"1","key":"10.1016\/j.neuropharm.2025.110783_bib50","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1007\/s10557-021-07229-4","article-title":"The function and regulation of platelet P2Y12 receptor","volume":"37","author":"Li","year":"2023","journal-title":"Cardiovasc. Drugs Ther."},{"issue":"5","key":"10.1016\/j.neuropharm.2025.110783_bib51","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1038\/nm1735","article-title":"A new penumbra: transitioning from injury into repair after stroke","volume":"14","author":"Lo","year":"2008","journal-title":"Nat. Med."},{"key":"10.1016\/j.neuropharm.2025.110783_bib52","doi-asserted-by":"crossref","DOI":"10.1007\/978-3-031-87919-7_12","article-title":"Oligodendrocyte and myelin pathophysiology in multiple sclerosis","volume":"317\u2013361","author":"L\u00f3pez-Muguruza","year":"2025","journal-title":"Adv. Neurobiol."},{"issue":"9","key":"10.1016\/j.neuropharm.2025.110783_bib53","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.3174\/ajnr.A2026","article-title":"Evaluation of CT perfusion in the setting of cerebral ischemia: patterns and pitfalls","volume":"31","author":"Lui","year":"2010","journal-title":"Am. J. Neuroradiol."},{"issue":"1","key":"10.1016\/j.neuropharm.2025.110783_bib54","doi-asserted-by":"crossref","first-page":"2711","DOI":"10.1038\/s41467-019-10626-x","article-title":"P2X7 receptor induces mitochondrial failure in monocytes and compromises NLRP3 inflammasome activation during sepsis","volume":"10","author":"Mart\u00ednez-Garc\u00eda","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.neuropharm.2025.110783_bib55","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2025.117862","article-title":"Positive allosteric modulators of purinergic P2X4 receptors: design, synthesis and therapeutic potential of \u201cclick\u201d ligands for multiple sclerosis","author":"Mata","year":"2025","journal-title":"Eur. J. Med. Chem."},{"issue":"4","key":"10.1016\/j.neuropharm.2025.110783_bib56","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/S0166-2236(00)01746-X","article-title":"The link between excitotoxic oligodendroglial death and demyelinating diseases","volume":"24","author":"Matute","year":"2001","journal-title":"Trends Neurosci."},{"issue":"2","key":"10.1016\/j.neuropharm.2025.110783_bib57","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1002\/glia.20275","article-title":"Glutamate\u2010mediated glial injury: mechanisms and clinical importance","volume":"53","author":"Matute","year":"2006","journal-title":"Glia"},{"issue":"35","key":"10.1016\/j.neuropharm.2025.110783_bib58","doi-asserted-by":"crossref","first-page":"9525","DOI":"10.1523\/JNEUROSCI.0579-07.2007","article-title":"P2X(7) receptor blockade prevents ATP excitotoxicity in oligodendrocytes and ameliorates experimental autoimmune encephalomyelitis","volume":"27","author":"Matute","year":"2007","journal-title":"J. Neurosci."},{"key":"10.1016\/j.neuropharm.2025.110783_bib59","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/j.brainres.2005.12.010","article-title":"The selective A2A receptor antagonist SCH 58261 protects from neurological deficit, brain damage and activation of p38 MAPK in rat focal cerebral ischemia","volume":"1073","author":"Melani","year":"2006","journal-title":"Brain Res."},{"issue":"6","key":"10.1016\/j.neuropharm.2025.110783_bib60","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1093\/brain\/awp076","article-title":"Selective adenosine A2a receptor antagonism reduces JNK activation in oligodendrocytes after cerebral ischaemia","volume":"132","author":"Melani","year":"2009","journal-title":"Brain"},{"issue":"3","key":"10.1016\/j.neuropharm.2025.110783_bib61","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1096\/fj.09-141275","article-title":"Activation of cannabinoid 2 receptors protects against cerebral ischemia by inhibiting neutrophil recruitment","volume":"24","author":"Murikinati","year":"2010","journal-title":"FASEB J."},{"key":"10.1016\/j.neuropharm.2025.110783_bib62","doi-asserted-by":"crossref","DOI":"10.3389\/fncel.2021.662935","article-title":"Role of P2X7 receptors in immune responses during neurodegeneration","volume":"15","author":"Oliveira-Giacomelli","year":"2021","journal-title":"Front. Cell. Neurosci."},{"key":"10.1016\/j.neuropharm.2025.110783_bib63","doi-asserted-by":"crossref","DOI":"10.3389\/fstro.2022.1093386","article-title":"Advances in PET imaging of ischemic stroke","volume":"1","author":"Orhii","year":"2023","journal-title":"Front. Stroke"},{"issue":"5","key":"10.1016\/j.neuropharm.2025.110783_bib64","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/j.ceca.2011.08.002","article-title":"Gain-of-function of P2X7 receptor gene variants in multiple sclerosis","volume":"50","author":"Oyanguren-Desez","year":"2011","journal-title":"Cell Calcium"},{"issue":"1","key":"10.1016\/j.neuropharm.2025.110783_bib65","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1038\/s41419-025-07897-2","article-title":"P2X7 a new therapeutic target to block vesicle-dependent metastasis in colon carcinoma: role of the A2A\/CD39\/CD73 axis","volume":"16","author":"Pegoraro","year":"2025","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.neuropharm.2025.110783_bib66","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2020.114385","article-title":"P2X7 receptor and the NLRP3 inflammasome: partners in crime","volume":"187","author":"Pelegrin","year":"2021","journal-title":"Biochem. Pharmacol."},{"issue":"2","key":"10.1016\/j.neuropharm.2025.110783_bib67","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/s11302-009-9141-7","article-title":"The P2X7 receptor\u2013pannexin connection to dye uptake and IL-1\u03b2 release","volume":"5","author":"Pelegrin","year":"2009","journal-title":"Purinergic Signal."},{"key":"10.1016\/j.neuropharm.2025.110783_bib68","doi-asserted-by":"crossref","first-page":"4340","DOI":"10.1038\/s41598-017-04292-6","article-title":"Kca3.1 activation via P2y2 purinergic receptors promotes human ovarian cancer cell (Skov-3) migration","volume":"7","author":"Robles-Mart\u00ednez","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.neuropharm.2025.110783_bib69","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1002\/humu.23218","article-title":"Purinergic receptors P2RX4 and P2RX7 in familial multiple sclerosis","volume":"38","author":"Sadovnick","year":"2017","journal-title":"Hum. Mutat."},{"key":"10.1016\/j.neuropharm.2025.110783_bib70","doi-asserted-by":"crossref","first-page":"52","DOI":"10.3389\/fphar.2018.00052","article-title":"The P2X7 receptor in inflammatory diseases: angel or demon?","volume":"9","author":"Savio","year":"2018","journal-title":"Front. Pharmacol."},{"issue":"1","key":"10.1016\/j.neuropharm.2025.110783_bib71","doi-asserted-by":"crossref","first-page":"6525","DOI":"10.1038\/s41467-024-50190-7","article-title":"Disease-relevant upregulation of P2Y1 receptor in astrocytes enhances neuronal excitability via IGFBP2","volume":"15","author":"Shigetomi","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.neuropharm.2025.110783_bib72","first-page":"5","article-title":"GABAA receptors: post-synaptic co-localization and cross-talk with other receptors","volume":"22","author":"Shrivastava","year":"2011","journal-title":"Front. Cell. Neurosci."},{"key":"10.1016\/j.neuropharm.2025.110783_bib73","doi-asserted-by":"crossref","first-page":"103","DOI":"10.3389\/fnmol.2020.00103","article-title":"Methyltransferase 3 mediated miRNA m6A methylation promotes stress granule formation in the early stage of acute ischemic stroke","volume":"13","author":"Si","year":"2020","journal-title":"Front. Mol. Neurosci."},{"issue":"10","key":"10.1016\/j.neuropharm.2025.110783_bib74","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/j.tips.2014.08.002","article-title":"P2X7 receptor: an emerging target in central nervous system diseases","volume":"35","author":"Sperl\u00e1gh","year":"2014","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.neuropharm.2025.110783_bib75","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1007\/978-3-540-89615-9_17","article-title":"Adenosine receptors and neurological disease: neuroprotection and neurodegeneration","volume":"139","author":"Stone","year":"2009","journal-title":"Handb. Exp. Pharmacol."},{"key":"10.1016\/j.neuropharm.2025.110783_bib76","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2020.554089","article-title":"Enhancing brain plasticity to promote stroke recovery","volume":"11","author":"Su","year":"2020","journal-title":"Front. Neurol."},{"issue":"9","key":"10.1016\/j.neuropharm.2025.110783_bib77","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1007\/s10495-019-01556-6","article-title":"Apoptosis regulation in the penumbra after ischemic stroke: expression of pro-and antiapoptotic proteins","volume":"24","author":"Uzdensky","year":"2019","journal-title":"Apoptosis"},{"issue":"2","key":"10.1016\/j.neuropharm.2025.110783_bib78","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1002\/glia.22596","article-title":"P2X4 receptors control the fate and survival of activated microglia","volume":"62","author":"V\u00e1zquez-Villoldo","year":"2014","journal-title":"Glia"},{"key":"10.1016\/j.neuropharm.2025.110783_bib79","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.neuropharm.2015.10.030","article-title":"Pharmacology and structure of P2Y receptors","volume":"104","author":"von K\u00fcgelgen","year":"2016","journal-title":"Neuropharmacology"},{"issue":"8","key":"10.1016\/j.neuropharm.2025.110783_bib80","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1038\/nm1082","article-title":"P2X7 receptor inhibition improves recovery after spinal cord injury","volume":"10","author":"Wang","year":"2004","journal-title":"Nat. Med."},{"issue":"8","key":"10.1016\/j.neuropharm.2025.110783_bib81","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0070927","article-title":"Microglial P2Y12 deficiency\/inhibition protects against brain ischemia","volume":"8","author":"Webster","year":"2013","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.neuropharm.2025.110783_bib82","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1186\/s12974-022-02601-z","article-title":"Blocking P2X7 by intracerebroventricular injection of P2X7-specific nanobodies reduces stroke lesions","volume":"19","author":"Wilmes","year":"2022","journal-title":"J. Neuroinflammation"},{"issue":"2","key":"10.1016\/j.neuropharm.2025.110783_bib83","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1007\/s11011-014-9560-1","article-title":"GABA receptors in brain development, function, and injury","volume":"30","author":"Wu","year":"2015","journal-title":"Metab. Brain Dis."},{"issue":"1","key":"10.1016\/j.neuropharm.2025.110783_bib84","article-title":"Purinergic neurotransmission receptor P2X4 silencing alleviates intracerebral hemorrhage-induced neuroinflammation by blocking the NLRP1\/Caspase-1 pathway","volume":"13","author":"Wu","year":"2023","journal-title":"Sci. Rep."},{"key":"10.1016\/j.neuropharm.2025.110783_bib85","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1186\/s12974-017-0865-y","article-title":"Activation of P2X7 receptor and NLRP3 inflammasome assembly in hippocampal glial cells mediates chronic stress-induced depressive-like behaviors","volume":"14","author":"Yue","year":"2017","journal-title":"J. Neuroinflammation"},{"issue":"8","key":"10.1016\/j.neuropharm.2025.110783_bib86","doi-asserted-by":"crossref","DOI":"10.15252\/emmm.201708743","article-title":"P2X4 receptor controls microglia activation and favors remyelination in autoimmune encephalitis","volume":"10","author":"Zabala","year":"2018","journal-title":"EMBO Mol. Med."},{"issue":"1","key":"10.1016\/j.neuropharm.2025.110783_bib87","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-026-54497-x","article-title":"P2X7 receptor suppression preserves blood-brain barrier through inhibiting RhoA activation after experimental intracerebral hemorrhage in rats","volume":"6","author":"Zhao","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.neuropharm.2025.110783_bib88","article-title":"Role and therapeutic targets of P2X7 receptors in neurodegenerative diseases","volume":"15","author":"Zheng","year":"2024","journal-title":"Front. Immunol."}],"container-title":["Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390825004915?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390825004915?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T15:17:26Z","timestamp":1781191046000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0028390825004915"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":87,"alternative-id":["S0028390825004915"],"URL":"https:\/\/doi.org\/10.1016\/j.neuropharm.2025.110783","relation":{},"ISSN":["0028-3908"],"issn-type":[{"value":"0028-3908","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Purinergic signaling in Stroke and Multiple Sclerosis: Prospects for therapies","name":"articletitle","label":"Article Title"},{"value":"Neuropharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neuropharm.2025.110783","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"110783"}}